Quantcast

Entyvio shows superiority over Humira in first head-to-head biologic study in ulcerative colitis

Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis

Read more

Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai get approval of Safinamide for Parkinson’s Disease in Japan

Italian biopharmaceutical specialist for nervous diseases solutions, Newron Pharmaceuticals, and it’s partners Meiji Seika Pharma together with Eisai, got approval to produce and sell Equifina tablets in Japan.

Read more

Daiichi Sankyo’s U3-1402 show reduction in tumor size in testing

Daiichi Sankyo’s test of HER3 antibody drug conjugate U3-1402 data suggest that targeting HER3 with may be an effective treatment strategy irrespective of mechanism of resistance identified in the setting of EGFR TKI resistance, where new precision treatments are needed, said Helena Yu, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, and a trial investigator.

Read more